VHPB Centre for Evaluation of Vaccination (CEV) |
Executive Secretary Administrative and Scientific Secretariat |
privacy statement
|
March 15-16, 2018 - Lisbon, Portugal
Meeting objectives:
Part 1: Vaccine shortage
Part 2: New Hepatitis B treatment
Background document - 2.6Mb (.pdf)
Thursday 15 March
Part 1: Vaccine shortage
SESSION 1: OPENING AND OBJECTIVES
Chairs: Rui Tato Marinho – Pierre Van Damme
09:00 – 09:20
SESSION 2: VACCINE SHORTAGE _ DEFINITIONS
09:20 - 09:40 Definitions of vaccine shortages - 781Kb (.pdf)
Oleg Benes
09:40 - 09:50 Questions and discussion
SESSION 3: MANUFACTURING OF VACCINES, WHAT CAN INFLUENCE THE VACCINE SUPPLY, COMPLEXITY OF VACCINE MANUFACTURING
09:50 - 10:30 Vaccine Europe - 1.7Mb (.pdf)
Michel Stoffel
10:30 - 10:50 Questions and discussion
10:50 – 11:10 Coffee break
SESSION 4: HEPATITIS A AND B VACCINE SHORTAGE (POTENTIAL) IMPACT ON PUBLIC HEALTH
Chairs: Paolo Bonanni – Alessandro Zanetti
11:10 – 11:30 Survey among VHPB advisors: Current overview of hepatitis A and Hepatitis B vaccine shortage - 1.5Mb (.pdf)
VHPB Secretariat
EXAMPLES FROM THE FIELD
11:50 – 12:10 Germany – Paul Ehrlich Institute - 1.8Mb (.pdf)
Isabelle Bekeredjian-Ding
318318
12:10 – 12:30 The Netherlands – RIVM - 318kb (.pdf)
Truus de Graaf
12:50 – 13:10 Questions & Comments
13:10- 14:15 Lunch
SESSION 5: THE ROLE OF THE DIFFERENT EUROPEAN STAKEHOLDERS IN CASE OF VACCINE SHORTAGE
Chairs: Vladimir Chulanov – Angela Dominguez
14:15– 14:35 WHO - 2.3Mb (.pdf)
Oleg Benes
14:35 – 14:55 ECDC
Tarik Derrough
14:55 – 15:15 EU MEDICINE AGENCY - EMA - 1.2Mb (.pdf)
Brendan Cuddy
15:15 – 15:30 Questions and discussion
15:35 – 15:55 Coffee break
SESSION 6: INITIATIVES TAKEN TO PREVENT VACCINE SHORTAGES OR TO MINIMIZE THE IMPACT
Chairs: Mira Kojouharova – Antons Mozalevskis
15:55 – 16:15 UK – Public Health UK - Hepatitis B: Vaccine recommendations during supply constraints - 624Kb (.pdf)
Sema Mandal
16:15 – 16:35 USA – Tracking Vaccine shortages and ACIP recommendations - 840Kb (.pdf)
John Ward
16:35 – 16:45 Question and discussion
SESSION 7: PANEL DISCUSSION: ACTIONS THAT ARE NEEDED TO AVOID VACCINE SHORTAGE IN THE FUTURE AND TO MINIMIZE THE IMPACT OF HEPATITIS VACCINE SUPPLY CONSTRAINTS ON PUBLIC HEALTH
Chairs: Johannes Hallauer – Daniel Lavanchy
16:45 – 18:00 Panel discussion/ Workshop
SESSION 8: CONCLUSIONS
18:00 – 18:15 Wrap up of the meeting Part 1: Vaccine Shortage - 571b (.pdf)
David FitzSimons
Friday 16 March
Part 2: New Hepatitis B treatment
SESSION 9: OVERVIEW NEW TREATMENT/TREATMENT STRATEGIES FOR HEPATITIS B IN THE PIPELINE
Chairs: Daniel Shouval – Fiona Godfrey
09:00 – 09:30 New treatment - Review based on: Novel targets for hepatitis B virus therapy. - 4.7Mb (.pdf)
Barbara Testoni
09:30 – 09:50 Treatment guidelines (EASL) - 740Kb (.pdf)
Pietro Lampertico
09:50 – 10:10 What is new on HBsAg and other diagnostic markers in HBV infection? - 1.7Mb (.pdf)
Christoph Höner zu Siederdissen
10:10 – 10:30 Questions & Comments
10:30 – 10:50 Coffee break
SESSION 10: IMPACT ON PUBLIC HEALTH OF NEW TREATMENTS AND HOW CAN POLICY MAKERS BE PREPARED
Chairs: Antons Mozalevskis – Helena Cortez-Pinto
10:50 – 11-10 Elimination of Hepatitis B: Is It a Mission Possible - 1.5Mb (.pdf)
Tai-Chung Tseng
11:10 – 11-30 The cost-effectiveness of hepatitis B case-finding interventions in the UK -1.5Mb (.pdf)
Jack Williams
11:30 – 11-50 Challenges in warranting access to prophylaxis and therapy for hepatitis B virus infection - 1Mb (.pdf)
Christoph Höner zu Siederdissen
11:50 – 12-10 Questions & Comments
SESSION 11: DISCUSSION SESSION INVESTIGATE THE PUBLIC HEALTH NEEDS TO IMPLEMENT HEPATITIS B TREATMENT PROTOCOLS IN THE EUROPEAN COUNTRIES AND THE IMPACT THEY WILL HAVE ON THE WHO’S HEPATITIS ELIMINATION GOALS
Chairs: Mojca Matičič – Tatjana Reic
12:10 – 13-10 Panel discussion -1.5Mb (.pdf)
13:10 – 14-30 Lunch
SESSION 12: CONCLUSIONS OF THE MEETING
Chairs: Pierre Van Damme – Rui Tato Marinho
14:30 – 15:00 Wrap up of part 2: New Hepatitis B Treatment - 462b (.pdf)
David FitzSimons